British drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. GSK acquired a 19,9% equity stake in Orchard and a board membership.
A public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics Board of Directors. Alexions SEK232/share bid would total in an acqusition price of SEK6.564bn or €638.8m.
The Eppendorf DASbox mini bioreactor system with its small working volume, compact design, as well as advanced control, and information management options is ideal for research and early development processes.
Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis Inc, whose SMA gene therapy AVXS-101 is in Phase III testing.
Commense, Inc., an affiliate of PureTech Health plc developing microbiome-derived immune modulators for paediatric and maternal health, today announced the appointment of Edward J. Tad Stewart as President and Chief Executive Officer.
A newly developed blood test indicates Alzheimer’s disease on average eight years before the clinical diagnosis.
Human drug trials are compromised by poor reporting and potential bias of animal research. German researchers analysed more than 700 preclinical animal studies and investigator brochures provided by three medical centres. They call to establish documentation standards for IBs/preclinical dossiers.
Nordic Nanovector ASA announces that Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. A search for a new CEO will begin immediately. To ensure a smooth transition, Mr Costa has agreed to be available to the board until the end of July 2018.
French Ose Immunotherapeutics SA has licenced global commercialisation rights of its preclinical programme OSE-172 to Boehringer Ingelheim which hopes to complement its immunoncology portfolio with a tumour microenvironment modifier that reactivates effector T cell responses.
Smith & Nephew plc today announced the appointment of Namal Nawana as Chief Executive Officer. He will join the Company and be appointed to the Board as an Executive Director on 7 May 2018.